Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group. Matignon M, et al. Among authors: assoumou l. HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27. HIV Med. 2019. PMID: 30688008 Free article.
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study.
Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group. Costagliola D, et al. Among authors: assoumou l. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):12-8. doi: 10.1097/QAI.0b013e318074eb73. J Acquir Immune Defic Syndr. 2007. PMID: 17514016
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V. Soulié C, et al. Among authors: assoumou l. AIDS. 2007 Oct 18;21(16):2243-5. doi: 10.1097/QAD.0b013e3282f0e3d0. AIDS. 2007. PMID: 18090053
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group. Descamps D, et al. Among authors: assoumou l. J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13. J Antimicrob Chemother. 2008. PMID: 18552344
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.
Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D; Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research. Assoumou L, et al. J Infect Dis. 2008 Aug 15;198(4):470-80. doi: 10.1086/590156. J Infect Dis. 2008. PMID: 18598191
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. Among authors: assoumou l. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D; ANRS 121 Hippocampe study group. Duvivier C, et al. Among authors: assoumou l. AIDS. 2009 Apr 27;23(7):817-24. doi: 10.1097/QAD.0b013e328328f789. AIDS. 2009. PMID: 19363330 Clinical Trial.
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. Among authors: assoumou l. AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031. AIDS. 2009. PMID: 19487903 Clinical Trial.
121 results